The stock of Protalix BioTherapeutics Inc. (PLX) has seen a -5.05% decrease in the past week, with a -16.39% drop in the past month, and a -25.80% decrease in the past quarter. The volatility ratio for the week is 5.57%, and the volatility levels for the past 30 days are at 5.40% for PLX. The simple moving average for the last 20 days is -8.50% for PLX’s stock, with a simple moving average of -29.37% for the last 200 days.
Is It Worth Investing in Protalix BioTherapeutics Inc. (AMEX: PLX) Right Now?
Protalix BioTherapeutics Inc. (AMEX: PLX) has a higher price-to-earnings ratio of 36.26x compared to its average ratio, The 36-month beta value for PLX is at 0.91. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PLX is 62.49M, and currently, shorts hold a 10.34% of that float. The average trading volume for PLX on April 19, 2024 was 348.75K shares.
PLX) stock’s latest price update
Protalix BioTherapeutics Inc. (AMEX: PLX)’s stock price has dropped by -0.85 in relation to previous closing price of 1.13. Nevertheless, the company has seen a loss of -5.05% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-14 that Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08, 2020 of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at -18.12% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.44% of loss for the given period.
Volatility was left at 5.40%, however, over the last 30 days, the volatility rate increased by 5.57%, as shares sank -12.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.62% lower at present.
During the last 5 trading sessions, PLX fell by -1.69%, which changed the moving average for the period of 200-days by -35.56% in comparison to the 20-day moving average, which settled at $1.2165. In addition, Protalix BioTherapeutics Inc. saw -37.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLX starting from Bashan Dror, who purchase 64,516 shares at the price of $1.40 back on Oct 19 ’23. After this action, Bashan Dror now owns 132,516 shares of Protalix BioTherapeutics Inc., valued at $90,484 using the latest closing price.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.65 for the gross margin
The net margin for Protalix BioTherapeutics Inc. stands at 0.13. The total capital return value is set at 0.27. Equity return is now at value 72.50, with 11.86 for asset returns.
Based on Protalix BioTherapeutics Inc. (PLX), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.05. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is 3.28.
Currently, EBITDA for the company is 11.65 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.3. The receivables turnover for the company is 12.42for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.54.
Conclusion
In conclusion, Protalix BioTherapeutics Inc. (PLX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
